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Abstract
Background: A large trial to investigate the effectiveness of population based screening for chlamydia infections was
conducted in the Netherlands in 2008–2012. The trial was register based and consisted of four rounds of screening of
women and men in the age groups 16–29 years in three regions in the Netherlands. Data were collected on participation
rates and positivity rates per round. A modeling study was conducted to project screening effects for various screening
strategies into the future.
Methods and Findings: We used a stochastic network simulation model incorporating partnership formation and
dissolution, aging and a sexual life course perspective. Trends in baseline rates of chlamydia testing and treatment were
used to describe the epidemiological situation before the start of the screening program. Data on participation rates was
used to describe screening uptake in rural and urban areas. Simulations were used to project the effectiveness of screening
on chlamydia prevalence for a time period of 10 years. In addition, we tested alternative screening strategies, such as
including only women, targeting different age groups, and biennial screening. Screening reduced prevalence by about 1%
in the first two screening rounds and leveled off after that. Extrapolating observed participation rates into the future
indicated very low participation in the long run. Alternative strategies only marginally changed the effectiveness of
screening. Higher participation rates as originally foreseen in the program would have succeeded in reducing chlamydia
prevalence to very low levels in the long run.
Conclusions: Decreasing participation rates over time profoundly impact the effectiveness of population based screening
for chlamydia infections. Using data from several consecutive rounds of screening in a simulation model enabled us to
assess the future effectiveness of screening on prevalence. If participation rates cannot be kept at a sufficient level, the
effectiveness of screening on prevalence will remain limited.
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Introduction
Chlamydia infections are the most prevalent bacterial sexually
transmitted infection (STI) in the Netherlands with a prevalence of
around 2% in the adult population [1,2]. Prevalence is highest in
younger age groups and in urbanized areas. As Chlamydia
infections in women can cause long term complications such as
pelvic inflammatory disease (PID), ectopic pregnancy and
infertility [3], prevention is needed especially in young women.
Around 80% of infections in women and 50% of infections in men
are asymptomatic [4], implying identification of asymptomatic
infections is key for a successful control of the infection.
In the Netherlands, the implementation of a national Chla-
mydia screening program has been in discussion for many years
[5]. Pilot studies were conducted to investigate the feasibility of
opportunistic and population based screening, respectively [1,6],
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and cost effectiveness studies suggested that screening could be
cost-effective or even cost saving if implemented in certain age
groups [7–9]. A study to obtain baseline estimates of prevalence in
the general population was conducted in four regions in the
Netherlands, covering both urban and rural population [1]. To
support a final decision about implementation of a national
Chlamydia screening program a register-based screening imple-
mentation (Chlamydia Screening Implementation) was piloted in
three regions in the Netherlands in 2008–2012 [10–13].
To assess the long term effects of the Chlamydia Screening
Implementation (CSI) a dynamic network simulation model was
employed that took into account data on sexual behavior in the
Netherlands, uptake of chlamydia testing and treatment in regular
health care, and participation rates of screening as observed in the
CSI. Projections about future incidence of Chlamydia infections in
the heterosexual population were combined with a cost-effective-
ness study to estimate the cost per major outcome averted.
Here we report on results from the modeling study on
effectiveness of population based screening during the CSI and
projected ten years into the future. We investigated how the
impact on prevalence depends on participation rates and on
degree of urbanization. Finally we investigated the effects of
alternative screening strategies such as changes in screening
intervals and targeted age groups on population prevalence of
Chlamydia infection.
Methods
A dynamic sexual network model
We used a simulation model that describes a dynamic process of
partnership formation and dissolution in a heterosexual population
[14]. The population consisted of 50,000 individuals with a sex
ratio of 1:1 and a uniform distribution over the age range 13–64
years. Individuals were characterized by their sex, age, partnership
status and infection status. Sexual activity of an individual could
change during an individual’s life course with periods of high and
low rates of partner change. In periods of high sexual activity, the
capacity of an individual to form partnerships and maintain them
simultaneously was higher than in periods of low activity. In the
latter periods, individuals were restricted to monogamous part-
nerships of varying duration. Partnerships could be of three types
distinguished by their average durations and frequencies of sexual
intercourse. Sexual behavior parameters were fitted to data about
cumulative numbers of life time partners, age at sexual debut,
numbers of partners in last year by age and sex, durations of
partnerships and gaps between partnerships. The model popula-
tion is not stratified by ethnicity, neighborhood or educational
level. For details about model structure and fitting of those
variables we refer the reader to Schmid & Kretzschmar 2012 [14].
Parameter values used by the model are given in Table S1 in
Supplementary Information S1.
Sexual behavior data
We used data from a representative survey on sexual behavior
in the age group 15–70 conducted by Rutgers-WPF in 2008 in the
Netherlands [15]. The survey included 5402 respondents, 2499
males and 2903 females. We used the following variables to inform
the model: numbers of life time partners, numbers of partners in
the last 6 months, duration of current partnership, overlap
between partnerships with a new(,6 months) steady partner and
previous partners, degree of urbanization, age at first sex, and age
of partner. All variables were stratified by age and sex. We used
information from all respondents to parametrize sexual behavior
on the national level (in the following referred to as the national
level model), and data from those respondents living in highly
urbanized areas (.2500 addresses per km2) to parametrize a
model for the urban areas (referred to as the urbanized areas
model).
Some additional variables were used to inform the sexual
network model for which no information was available in the
Rutgers-WPF survey: these are the duration of the previous
partnership, the gap/overlap between the last two partnerships,
and the degree of assortative mixing between individuals of
different levels of sexual activity. For these variables we used the
information available in the NATSAL sexual behavior survey,
which included 11,161 respondents from the United Kingdom in
2000 [16]. We found the use of sexual behavior data from the UK
justified, because we found that both surveys showed reasonably
similar results for variables that were available in both data sets
(such as the cumulative numbers of life time partners), and that the
sexual network model could be adjusted to accommodate these
additional variables without deteriorating its fit to the information
available in the Rutgers-WPF survey [14].
Chlamydia transmission
Transmission of Chlamydia is implemented within the model as
the daily chance to transmit Chlamydia between an infected and
an uninfected partner. The Chlamydia transmission rate was
chosen such that the prevalence in both the national and urban
sexual network models matched the Chlamydia prevalence
reported for different urbanization degrees by van Bergen et al
[1]. The duration of untreated Chlamydia, and the incubation
time (which also defined the latent period) were taken from
[17,18], and are listed in Table S1 in Supplementary Information
S1. The fraction of infections that was symptomatic was set to 50%
for men, and 30% for women, based on the experience of an
expert panel composed of GPs and members of the Dutch STI
centers.
Chlamydia testing and treatment in regular health care
In the Netherlands, Chlamydia infections are diagnosed either
by general practitioners (GPs) or at STI clinics. The latter serve the
high risk population for sexually transmitted infections, whereas
the former diagnose infections also in the general population. If a
Chlamydia infection is diagnosed, antibiotic treatment is given and
an effort is made to notify and treat current and ex-partners.
Chlamydia infections are not notifiable in the Netherlands, but a
sentinel surveillance based on STI clinic diagnoses is used to
monitor trends in prevalence. In recent years, an increasing trend
was observed in the numbers of consultations for STI testing at
STI clinics, however positivity rates remained fairly stable [19]. A
substantial fraction of cases are diagnosed and treated by GPs and
are not reported to national surveillance [20]. In 2001, Chlamydia
prevalence was measured in the general population in a sample of
3458 men and 4925 women [1]. Prevalence was 2.5% among
women and 1.5% among men, with higher prevalence in younger
age groups and a clear association of high prevalence with degree
of urbanization.
In the model, we assumed that there is a group of 9% of the
population that never seeks health care for Chlamydia infections
even when they are symptomatic [21]. This population group is
also not compliant with requests from their partners to seek
treatment in the context of partner notification. For the remaining
population, individuals with symptomatic infections will seek
healthcare. We assumed that symptoms develop after an
incubation period of 14 days, and that individuals visit a GP after
appearance of symptoms with a median delay of 16 days (sampled
from an exponential distribution). In the model, symptomatic men
Chlamydia Screening and Participation
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receive treatment and clear the infection immediately after their
visit to the GP. For symptomatic women, it takes an additional 8
days after visiting a GP until there is laboratory confirmation of a
positive Chlamydia test, after which they immediately receive
treatment and clear the infection [22]. Individuals with asymp-
tomatic infections seek healthcare with a rate estimated from data
about GP and STI center consultations [19]. If they are diagnosed
positive for Chlamydia, they receive treatment and clear the
infection immediately. When in the model a Chlamydia infection
is diagnosed by the GP or laboratory, an average of 40% of
current partners are treated for Chlamydia as well [23]; in the
model partners are treated on the same day as the infected index
case. We assumed a Chlamydia test sensitivity of 98%, a
Chlamydia test specificity of 99.6% [24], and a treatment success
rate of 97% [25]. The testing and treatment of symptomatic and
asymptomatic Chlamydia infections as described here forms the
baseline healthcare level against which the effect of the
screening implementation is tested. See also tableoˆ 1 for a
summary of assumptions regarding screening and treatment.
Chlamydia Screening Implementation data
The CSI was carried out in three regions in the Netherlands, in
which different screening procedures were set up in order to be
able to evaluate the impact of screening on prevalence after 3
subsequent screening rounds. In the CSI, both men and women in
the age group 15–29 yearly received an invitation to participate in
screening. Invitations were personalized letters including the
address of the program website and a secure login code through
which eligible participants could request a kit for self-sampling. In
the less urbanized areas, the expected chlamydia prevalence was
lower than in the big cities and therefore, a selection through risk
score based on data from a prior pilot chlamydia screening project
was used. Scores were based on age, urban/non-urban residence,
level of education, ethnic background, condom use, number of
lifetime and recent sex partners, and presence of STI-related
symptoms, as reported in a short online questionnaire to be
answered before ordering a test kit [11,26]. For more detail, we
refer the reader to [10–12]. Tablesoˆ 1 and 2 describe how those
procedures were defined in the simulation model. Tableoˆ 3 shows
numbers of participants per screening year. Partner notification
rates were around 80% in the CSI and therefore higher than
observed in earlier GP based studies.
Approval for this study was obtained from the Medical Ethics
Committee of the Free University of Amsterdam. The study is also
registered in the NTR 3071 (Netherlands Trial Register, www.
trialregister.nl). Informed consent was given by application for a
test kit in writing via an online project website, and this consent
procedure was approved by the ethics committee.
Participation trees
We describe changes over time in participation rates based on a
so-called participation tree, i.e. a scheme that defines the
probability of an individual to participate in screening depending
on his/her previous participation decision (Figureoˆ 1). If an
individual is offered screening for the first time, he/she participates
with a probability that depends on gender and year since the roll-
out of the screening program. Factors describing decline of initial
participation from one year to the next are given in Tableoˆ 1. In
subsequent screening rounds, the individual gets a new offer and
now the probability to participate depends on the history of
participation decisions of that individual. After 4 screening rounds
each participant can be characterized by a sequence of YES and
NO describing whether or not he/she participated in a particular
round. We stratified the data set according to unique sequences of
YES and NO. From these sub data sets the percentages in the
participation trees were computed. The same data was used to
validate the assumption that subsequent screening rounds only
depend on the previous choices that an individual has made. This
was done by comparing the participation trees based only on
participation decisions of individuals starting CSI in 2008 with
those of individuals starting in later years.
Participation trees are extrapolated beyond the fourth round
(the last round for which we have CSI participation information)
by assuming that in the fifth and subsequent rounds, the ratio of
participants and non-participants remains stable, that is remains
equal to the ratio of participants and non-participants observed in
the fourth round in that branch of the tree. As an example, in
Figureoˆ 1 the extrapolation is shown for one particular branch of
the tree, which shows how the chances of accepting and declining
a fifth invitation are the same as for the fourth invitation (i.e. 17%
and 83%). This is the simplest extrapolation possible; although
more sophisticated ways of extrapolating participation can be
defined based on the participation data, the impact on the model
results using such extrapolations was found to be very small.
Screening scenarios
National level model versus urbanized areas model. We
considered two types of populations, one that represented the
general population on the national level, and another one that
represented urbanized areas only. For the model on the national
level, the data from the complete RUTGERS-WPF sexual
behavior survey was used and it was assumed that there was a
selection for screening based on risk scores. For the model
describing urbanized areas, we used sexual behavior data only
from individuals from highly urbanized areas and there was no risk
score selection.
CSI screening scenario. The CSI screening scenario
describes screening as implemented in the CSI project
[11,12,27]. In short: in the CSI, both men and women in the
age group 15–29 are assigned a particular week number, in which
they yearly receive an invitation to participate in screening. The
time between invitation and actual treatment of those found
positive depends on the time that it takes individuals to respond to
their invitation, get a sampling kit, return the sample, and if tested
positive, acquire treatment [28]. Participation of individuals in the
simulation model was implemented as described above, with the
additional assumption that all the described delays are constant
over time. This allowed us to assign a week number to every
individual in the model that reflects their invitation week and
personal delay until treatment. Individuals who tested positive,
complied with treatment with probability 0.86, and were treated
immediately (Tableoˆ 1).
Alternative screening scenarios. We considered four alter-
native screening scenarios:
N Screening women only
N As the long-term harmful effects of Chlamydia almost
exclusively affect women, screening women only (and their
partners after positive initial test results) may be a more cost
effective strategy.
N Screening the age group 16–24
N As Chlamydia prevalence is generally thought to be highest in
the age range of 16–24, targeting the screening to that age-
group may be more cost-effective. Screening programs in other
countries indeed target to the age range 16–24 years [29].
N Screening the age group 26–29
Chlamydia Screening and Participation
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N Peak prevalence in men is in older age groups, so targeting
those age groups may also have considerable effects on
younger women.
N Biennial screening
N Screening individuals once every two years rather than
annually may prevent participation exhaustion by inviting
participants less frequently. Participation retention in the
biennial screening scenario is handled as follows: only half the
eligible CSI group participates gets their first invite in 2008,
the other half gets their first invite in 2009. First time
Table 1. Screening rules implemented in the model.
Screening design Rule as implemented in the model Comments Reference
1 Time of invitation Each individual is assigned a number which indicates
the week of the year that they are invited for CSI
screening.
2 Eligibility Individuals are eligible to participate if they are in the
age group 16–29 years and meet the criteria for
inclusion (e.g. have been sexually active, and for the
national level model, pass a risk-score threshold to
exclude those persons with negligible risk levels).
In the model, individuals who turn 16 during the
year are invited for the first time in the following
year; this might be slightly different in reality, where
they might still be invited the same year they turn 16,
depending on the exact timing of invitations per
geographic area.
3 Risk score selection The risk score is explained in tableoˆ 2. It excludes
about 20% of the lower-risk sexually active
population in the age-range of 16–29.
The risk score is similar to the risk score-based
selection applied in one of the CSI regions. As
the model population was not stratified by level of
education or ethnicity, the risk score threshold for
inclusion used in the model was lower than
the .= 6 threshold used in the CSI to exclude a
similar fraction of 20–30% of the population as was
excluded by risk score in the CSI screening.
[26] [13]
4 Acceptance of first
invitation
The chance that an individual accepts his/her first
screening invitation depends solely on their gender,
and the number of years since start of the screening
program Initial participation decreases for both
genders over time.
Factors for decrease of initial participation over time
are 2008: 1.0 2009: 0.82 2010: 0.675 2011: 0.438 2012
and further: 0.37 times participation in 2008.
5 Repeated acceptance Repeated participation depends solely on an
individual’s previous decisions on participation. The
chance to participate per screening round is detailed
in figureoˆ 1.
6 Treatment uptake 14% of participants ignore positive test results, and
do not seek treatment. In the model there is no
correlation between these 14% and the 9% of the
population that do not participate in baseline
healthcare. 86% of those tested positive get
treatment.
In the CSI 91% sought treatment after being
informed positive, 94% of those 91% actually
took the treatment.
[39], page 46
7 Treatment of current
partners
80% of current partners of individuals treated for
Chlamydia are notified and treated at the same time
as the index case. The 20% of the current partners
that are not treated includes the 14% that would
ignore their own positive test results (point 6), and
individuals who have been tested or treated
themselves recently (a personal value for each
individual, drawn from an exponential distribution
with a median of 68 days).
‘‘recent testing/treatment fatigue’’ determines
whether individuals are willing to participate in
testing and/or treatment as part of symptomatic
and asymptomatic regular healthcare, as well as
part of all forms of partner notification (both regular
healthcare and CSI), for a number of days after their
latest Chlamydia testing and/or treatment. Participation
in the CSI program in the model is not affected by this
fatigue, as the participation data upon which the
participation trees are based already implicitly contains
this information (on a population level)
[40]
8 treatment of
ex-partners
50% of ex-partners for which the partnership ended
less than one year ago are notified and treated. The
50% of the recent ex-partners that are not treated
include the 14% that would ignore their own
positive test results, as well as those that have been
treated recently. As a model simplification, treatment
of ex-partners happens immediately upon treating
the positively screened individual.
9 Retesting of those
tested positive
In the case of a positive test result, participants are
invited for an additional test 6 months after the
initial invitation. The procedure is identical to the
above procedure, except that the delay between
invitation and treatment is shorter by 17 days. The
effect is that people are re-treated (if positive) 166
days after their first test.
In the CSI these participants immediately get a
test-kit sent to their home, which shortens the
delay between an invitation to be retested and
actual treatment taking place by 17 days.
doi:10.1371/journal.pone.0058674.t001
Chlamydia Screening and Participation
PLOS ONE | www.plosone.org 4 March 2013 | Volume 8 | Issue 3 | e58674
participation is still determined by gender and year since
introduction of the CSI program, so the group that gets their
first invite in 2009 will have the first-time participation ratio
associated with 2009 (as in the other CSI simulations). The
time between invitations per individual is now 2 years, rather
than 1 year. This is assumed to have no effect as to how
individuals move through the participation trees (as we have
no data from which to estimate how participation trees might
change if invitations are send out once every two years).
As all four scenarios reduce the size of the target population of
the screening program as compared with the CSI screening, their
effects on Chlamydia prevalence will inevitably be less than that of
the CSI strategy. However, cost effectiveness of those alternative
strategies may more favorable.
Sensitivity analysis. Besides those alternative scenarios we
included two scenarios into our results that investigated sensitivity
of results on assumptions and model input. One is a scenario,
where we assumed a stable high participation rate for both men
and women. We included this to show how prevalence would have
developed if the CSI would have been more successful in
recruiting participants into screening. The CSI was set up with
the expectation that the participation rates of around 30% found
in the 1-year pilot study [1] could be maintained. This proved to
be wrong on two accounts: the fraction of initial invitees that
participated declined after the first year, and persons that were
invited a second and third time on average participated less than
they did in response to the previous invitations. On the national
level, we study the effect of an average 30% participation rate, split
into 19.9% for men, and 40.1% for women (the same relative
difference in participation rates between genders as observed in
CSI). On the urban level, we studied the effect of an average
25.6% participation rate (i.e. the same relative difference in
participation rates between the national and urban level as was
observed during CSI). Next, we also consider the possibility of high
levels of treatment failure, which by some estimates could be as
high as 8% [30,31]. In this scenario we assumed that the high level
of treatment failure occurred both in regular healthcare and in
CSI, and we re-fitted the daily Chlamydia transmission chance of
the model, such that the baseline Chlamydia prevalence in the
high treatment failure scenario remains similar to the baseline
Chlamydia prevalence in the main model. We compared the
impact of CSI with and without high levels of treatment failure.
Model implementation
For every scenario 40 simulation runs were conducted in a
population of 50,000 individuals and prevalence was averaged
over those simulation runs. To quantify the impact of screening in
the long run we compared with a baseline scenario in which no
screening was implemented. In the baseline scenario, Chlamydia
prevalence dropped slightly over time due to the increase of
Chlamydia testing and treatment in regular care as extrapolated
from observed trends [19]. We analyzed variability of results
across runs. We also performed simulations with smaller and
larger population sizes to ensure that the chosen population size
was sufficiently large to deliver stable results (not shown).
Results
For the CSI, the simulated national level prevalence at the
moment of implementation of screening was 2.5% in women and
1.5% in men (Tableoˆ 4). Prevalence dropped by 0.70 percentage
point (pp) in women and 0.41pp in men in the first year of
screening. After 3 years of screening, Chlamydia prevalence was
1.6% for women and 0.9% for men, i.e. a decrease in prevalence
by 0.92pp for women and 0.56pp for men as compared to
prevalence at start of screening, and a decrease of 0.86pp for
women and 0.56pp for men compared to the Chlamydia
prevalence in the baseline scenario at the beginning of 2011.
From 2011 onward, the additional effect of screening on
Chlamydia prevalence compared to the baseline scenario
Table 2. Risk score calculation.
Variable Risk Score
Age less than or equal to 19 +1, else +0
Lifetime partners 1 +0
Lifetime partners 2–5, +2 for men, +3 for women
Lifetime partners 6+ +3 for men, +5 for women
New relationship in last 6 months? +1, else +0
Cutoff value for men: 20% has a risk-score,2, and is excluded from screening
Cutoff value for women: 18% has a risk-score,3, and is excluded from screening
doi:10.1371/journal.pone.0058674.t002
Table 3. The numbers of men and women, who participated in the CSI per year of screening.
Men yes Men no participation rate (%) Women Yes Women no participation rate (%)
2008 13176 109847 10.7 28853 104932 21.6
2009 10625 138285 7.1 24201 135088 15.2
2010 8722 144721 5.7 20610 142234 12.7
2011 1152 44135 2.5 2962 43159 6.4
The total numbers of men and women differ between years, mainly because both in 2008 and in 2011 the CSI program did not run during the whole year.
doi:10.1371/journal.pone.0058674.t003
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remained constant (Figureoˆ 2A). The absolute impact of screening
was largest in the age groups 21–29 years for both men and
women and lower for age groups outside of the targeted age range
for both men and women (Figureoˆ 3).
For the CSI screening scenario in the highly urbanized areas,
Chlamydia prevalence at the time of implementation of the
screening program was 3.8% in women and 3.0% in men
(Tableoˆ 4). Prevalence then dropped by 1.04pp in the first year of
screening in women, and by 0.82pp in men. Chlamydia
prevalence in the screening scenario reached a minimum of
2.4% in women and 1.9% in men at the beginning of 2011, but
then increased again until the beginning of 2018, where it reaches
a level of 2.6% for women and 2.1% for men. The Chlamydia
prevalence for the CSI screening scenario in 2018 is 1.22pp lower
for women, and 0.92pp lower for men, compared to the
Chlamydia prevalence at the start of screening at the beginning
of 2008; however, due to a predicted continuing decline in
Chlamydia prevalence in the urban baseline scenario the
prevalence in 2018 is only 0.82pp lower for women, and 0.68pp
lower for men compared to the baseline scenario Chlamydia
Figure 1. Participation trees for women andmen. First-time participation was modelled to depend only on gender (panel A for women, panel B
for men), and year since the start of the screening program. Subsequent participation depended solely on the previous choices made. All rates are
based on observed participation rates in subsequent rounds of CSI. The extrapolation for years after the 4 years of CSI is based on results of the fourth
round as described in the text.
doi:10.1371/journal.pone.0058674.g001
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Figure 2. Effect of CSI on population prevalence of Chlamydia infections. The projected Chlamydia prevalence for men (solid lines) and
women (dashed lines) for the baseline scenario, CSI screening, and alternative scenarios. Panel A shows the projected prevalence on the national
level, Panel B shows the projected prevalence in urbanized areas.
doi:10.1371/journal.pone.0058674.g002
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Figure 3. Effect of CSI on population prevalence of Chlamydia infections by age category, on the national level. Prevalence levels are
shown for a scenario without screening implementation (‘‘baseline 2011’’), and after 3 (‘‘CSI 2011’’) and 10 years (‘‘CSI 2018’’) of screening, for (A)
women and (B) men. Splitting the population into age-groups gives a detailed view on the effect of CSI screening in addition to baseline testing and
treatment at GPs and STD clinics.
doi:10.1371/journal.pone.0058674.g003
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prevalence in 2018 (Figureoˆ 2B). Again the absolute impact of
screening was largest in the age groups 21–29 years for both men
and women and lower for age groups outside of the targeted age
range for both men and women (Figureoˆ 4). For the 16–20 year
old women the impact of screening was larger on national level
than in the urbanized areas.
For comparison, the prevalence estimates derived from the
positivity measures in the CSI program [13] are presented in
Tableoˆ 5.
Alternative scenarios
Screening women only. Despite the high success rate of
current partner notification (80%) in the CSI program, screening
women only is the least effective alternative scenario, reaching
only 50% of the decrease in prevalence that screening both men
and women achieves (Figureoˆ 2). This result is in contrast with an
earlier analysis [32], in which screening of men and women had
little additional value above screening women only. A key
difference between [32] and the present study is that the former
had a high and constant yearly participation rate of women in the
age-range 15–24.
Screening the age group 16–24 years. The initial decrease
in Chlamydia prevalence in the age group 16–29 years is smaller
when targeting to 16–24 year olds than in the CSI scenario,
because those of age 25–29 were not invited to participate.
However, on the national level the difference in prevalence
reduction when screening ages up to 24 or up to 29 becomes
marginal after 6 years of screening (Figureoˆ 2A). In urbanized
areas, the 16–24 scenario appears to be permanently less effective
than the CSI screening scenario (Figureoˆ 2B).
Although the peak of Chlamydia prevalence in women in
urbanized areas falls between the ages of 16 and 24, for men living
in an urban environment, and for both men and women in a non-
urban environment, the peak prevalence is at age 26–29
(Figuresoˆ 3 and 4). Therefore, when the aim of the program is
to maximize the reduction in Chlamydia prevalence, the CSI age
range of 16–29 would appear to be the best age range for a
nationwide screening program in the Netherlands.
Screening the age group 26–29 years. Targeting this older
age group only is clearly much less effective than all other
scenarios. Apparently, even if peaks in prevalence are observed in
those age groups, they are not the groups who are mainly driving
the transmission. The reason may be that persons in this age group
are recipients of infection, but not responsible for generating many
new secondary cases.
Biennial Screening. This scenario causes the largest de-
crease in Chlamydia prevalence of the tested alternative scenarios
at short term, but does not lead to a lower Chlamydia prevalence
than the CSI screening scenario in the long run. One assumption
in the biennial scenario is that participation rates are not affected
by the time interval between CSI invites, but only by the number
of invitations that an individual gets. As such, it takes longer for
individuals to become exhausted with CSI participation, and the
average number of years after which individuals permanently stop
participating doubles from 4.5 years to 9 years in urbanized areas.
A consequence of spreading participation over a longer time
period is shifting the age at which individuals participate to
correspond with the peak in Chlamydia prevalence, thus
increasing the effectiveness of screening.
Sensitivity analysis
The scenario with a high screening participation of around 30%
showed that prevalence can be reduced substantially in the long
run if participation on that level can be achieved (Figureoˆ 5). The
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prevalence levels reached after 10 years of screening were 0.21%
in women and 0.12% in men. The scenario considering high levels
of treatment failure showed only marginal impact of that
Figure 4. Effect of CSI on population prevalence of Chlamydia infections by age category, in urbanized areas. Prevalence levels are
shown for a scenario without screening implementation (‘‘baseline 2011’’), and after 3 (‘‘CSI 2011’’) and 10 years (‘‘CSI 2018’’) of screening, for (A)
women and (B) men. The effect on Chlamydia prevalence is most visible in the age-groups 21–25 for both women and men.
doi:10.1371/journal.pone.0058674.g004
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parameter on the effects of screening in the long run (Figure S1 in
Supplementary Information S1).
All results shown here are averages over 40 simulations with
50,000 individuals each. Despite these large samples, the estimated
average Chlamydia prevalence for the CSI age range showed
around 0.1pp variation over time in a population with a
Chlamydia prevalence of 1% and 2%, respectively. There was
considerable impact of stochasticity on prevalence per simulation
which was inherent to the transmission dynamics in the modeled
system: sexual contact networks follow a power-law distribution
[14,18,33], meaning that regardless of population size, there are
always a small number of individuals that are considerably more
sexually active than the majority of the population and will
therefore disproportionally impact on prevalence.
Discussion
In this modeling study we estimated that the effects of the CSI
program as implemented in 2008–2011 in three regions in the
Netherlands reduced Chlamydia prevalence in women aged 16–
29 by 1.18pp compared to the Chlamydia prevalence prior to the
start of the program, and 1.11pp compared to the baseline
Chlamydia prevalence in 2011. It is expected that this effect on
prevalence will shrink to 0.85pp if the screening program is
continued in future years due to a continued decline in
participation rates. The effectiveness of the screening program as
implemented now is limited by low participation rates and if
participation rates cannot be increased, a further reduction of
Chlamydia prevalence cannot be expected. The average size of the
effect of CSI on Chlamydia prevalence after 10 years of screening
for both genders combined is a decrease of 0.72pp in the general
population, and 0.75pp in highly urban areas. These results
concur with observations on positivity in CSI-data, especially for
non-urban settings, however, the observed decline in the empirical
data was smaller than in the model and was not statistically
significant [13]. If participation rates of 30% would have been
achieved as was originally foreseen for the CSI program, a
substantial impact on chlamydia prevalence would be possible in
the long run with a reduction on the national level of 2.25pp in
women and 1.36pp in men by the year 2018. The CSI study was
unique in that it collected participation data in several sequential
screening rounds in the same population. Using this information
for describing the development of participation rates over time in
the model enabled us to estimate the impact of declining
participation rates on the effectiveness of screening and to project
those effects on chlamydia prevalence to 2012–2018. The low and
waning participation levels limit the present and future effective-
ness of screening for all intervention strategies we investigated. If
continued participation cannot be ensured especially in high risk
groups prevalence reduction will remain marginal in the long run.
Secondly, the structure of the sexual contact network affects the
predicted effectiveness of CSI; the sexual contact patterns in the
model determine how partner change rates are distributed over
the population. This distribution in turn affects the age range in
which Chlamydia prevalence peaks and the speed with which
Chlamydia is transmitted through the network.
The model used here extends earlier models [32,34] by
including a more detailed description of sexual behavior param-
eters [14] and of the uptake of testing and treatment of Chlamydia
infections by regular health care. These improvements potentially
allow a more accurate projection of the effects of population based
screening on Chlamydia prevalence. Some modeling assumptions
are still simplified, such as the assumption that treatment leads to
clearance immediately, and that partners are treated simulta-
neously with their index case. These assumptions are optimistic
thereby making treatment and partner notification more effective
than more conservative assumptions would have done. As those
assumptions apply both to baseline testing and to screening
scenarios, they only have marginal influence on the comparison of
both. This is also confirmed by the minimal impact that higher
treatment failure rates have on screening success.
Earlier modeling results predicted a much larger impact of
population based screening on Chlamydia prevalence [32,35,36]
than shown here. The main reason for this discrepancy is that in
earlier studies screening was implemented in a baseline situation,
in which only symptomatically infected individuals were assumed
to be tested and treated and partner notification was not
performed. In the present model, screening was implemented on
Table 5. Prevalence estimates derived from positivity measures in the CSI program.
Chlamydia prevalence at first
invitation
Chlamydia prevalence at second
invitation
Chlamydia prevalence at third
invitation
year 2008 2009 2010
Limburg women 3.00% 2.80% 2.00%
men 2.40% 2.10% 1.30%
Amsterdam women 2.73% 2.68% 2.63%
men 2.50% 2.30% 2.31%
Rotterdam women 4.03% 3.61% 4.08%
men 3.33% 3.32% 3.81%
Chlamydia prevalence at first
invitation
Chlamydia prevalence at second
invitation
Chlamydia prevalence at third
invitation
national women 3.00% 2.80% 2.00%
men 2.40% 2.10% 1.30%
urban women 3.38% 3.15% 3.36%
men 2.92% 2.81% 3.06%
Prevalence rates for Amsterdam and Rotterdam are aggregated to come to an estimate for urban populations, while estimates for the Limburg area were used as
national level estimates. Estimates are only available for 2008–2010 [13].
doi:10.1371/journal.pone.0058674.t005
Chlamydia Screening and Participation
PLOS ONE | www.plosone.org 11 March 2013 | Volume 8 | Issue 3 | e58674
Figure 5. Effect of a high CSI participation rates on population prevalence of Chlamydia infections. In contrast to the reduction in
Chlamydia prevalence achieved by screening with the observed participation rates, CSI screening with a stable participation rate of 30% on national
level (A) and 25.6% in urbanized areas (B) would lead to a drastic reduction in Chlamydia prevalence in men (solid lines) and women (dashed lines).
On the national level, closed populations of 50,000 individuals are frequently unable to maintain Chlamydia in the population, and the average
Chlamydia prevalence reported in panel A is therefore a combination of simulated populations where Chlamydia has gone extinct, and where
Chlamydia is maintained at low prevalence levels.
doi:10.1371/journal.pone.0058674.g005
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top of a baseline level of testing and treating also asymptomatic
cases and a baseline rate of partner notification. In other words,
health care in the present situation in the Netherlands already
detects and treats substantial numbers of asymptomatic Chlamyd-
ia infections, so that additional population screening has a much
lower incremental effect on prevalence. Other recent modeling
studies investigating the question of how population based
screening performs incremental to existing care [37], or what
the effects are of improving performance of existing screening
programs [38] also found low impact of population based
screening on Chlamydia prevalence.
The two main conclusions to be drawn from modeling the
impact of CSI on Chlamydia prevalence are that a continuous CSI
screening effort will have a limited but stable effect on Chlamydia
prevalence, and that the size of this effect depends heavily on the
sustained participation rate of a screening program. As our efforts
to increase participation rates in the general population were not
successful, we need to focus prevention efforts on individuals with
highest risk by retesting those found positive and by intensifying
partner notification.
Supporting Information
Supplementary Information S1 Parameter values table and
additional figures.
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